Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2015

Open Access 01-12-2015 | Meeting abstract

PHLPP1 phosphatase inhibition in hypothalamus restores insulin signaling and action and reduces adiposity in obese rats

Authors: Bruna dos Santos Cardoso, Gisele Castro, Natália Ferreira Mendes, Paula Gabriele Fernandes Quaresma, Tamires Marques Zanotto, Mario Jose Abdalla Saad, Patrícia de Oliveira Prada

Published in: Diabetology & Metabolic Syndrome | Special Issue 1/2015

Login to get access

Excerpt

Obesity results from imbalance between food intake and energy expenditure. The energy homeostasis is regulated by hypothalamic neurons that receive different neural, hormonal and metabolic signals. Insulin is one of the main hormones that regulate energy homeostasis and acts through a cascade of intracellular signaling that depends on the activation of several proteins, such as Akt. Our hypothesis is that PH domain and Leucine rich repeat Protein Phosphatase 1 (PHLPP1) inhibits Akt activity by dephosphorylating serine 473 residues, impairing the insulin action in the hypothalamus. However, PHLPP1 expression and the role played by it on the hypothalamus of diet induced obesity (DIO) animals are not fully understood. …
Metadata
Title
PHLPP1 phosphatase inhibition in hypothalamus restores insulin signaling and action and reduces adiposity in obese rats
Authors
Bruna dos Santos Cardoso
Gisele Castro
Natália Ferreira Mendes
Paula Gabriele Fernandes Quaresma
Tamires Marques Zanotto
Mario Jose Abdalla Saad
Patrícia de Oliveira Prada
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue Special Issue 1/2015
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-7-S1-A131

Other articles of this Special Issue 1/2015

Diabetology & Metabolic Syndrome 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine